| Literature DB >> 29333090 |
Sun-Yeong Gwon1,2, Ki-Jong Rhee2, Ho Joong Sung1,3.
Abstract
The risk of rheumatoid arthritis (RA), an autoimmune disease, in the elderly population increases along with that of atherosclerosis, cardiovascular disease, type 2 diabetes, and Alzheimer's disease. Identifying specific biomarkers for RA can clarify the underlying molecular mechanisms and can aid diagnosis and patient care. To this end, the present study investigated the genes and proteins that are differentially expressed in RA using a mouse collagen-induced arthritis (CIA) model. We performed gene microarray and proteome array analyses using blood samples from the mice and found that 50 genes and 24 proteins were upregulated and 48 genes were downregulated by more than 2-fold in the CIA model relative to the control. The gene microarray and proteome array results were validated by evaluating the expression levels of select genes and proteins by real-time PCR and western blotting, respectively. We found that the level of integrin α2, which has not been previously reported as a biomarker of RA, was significantly increased in CIA mice as compared to controls. These findings provide a set of novel biomarkers that can be useful for diagnosing and evaluating the progression of RA.Entities:
Keywords: biomarker; collagen-induced arthritis; integrin α2.; microarray; proteome analysis
Mesh:
Substances:
Year: 2018 PMID: 29333090 PMCID: PMC5765742 DOI: 10.7150/ijms.22345
Source DB: PubMed Journal: Int J Med Sci ISSN: 1449-1907 Impact factor: 3.738
Figure 1Gross morphological and histological examination of CIA. (A) Gross observation of mouse paws. Shown are the fore paws (top) and hind paws (bottom) of control (n = 12) and CIA (n = 14) mice at 14 weeks of age. Scale bars = 10 mm. (B) H&E staining of sagittal sections of control and CIA mouse joints. Lower panels show enlarged views of the areas delineated by a box in the upper panels. Arrows indicate cartilage boundaries. Scale bars = 1 mm.
Genes differentially expressed in the blood of control and CIA mice
| Increased genes | Decreased genes | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | Gene symbol | Fold change | No. | Gene symbol | Fold change | No. | Gene symbol | Fold change | No. | Gene symbol | Fold change | |||
| 1 | 24.7 | 26 | 2.2 | 1 | -3.9 | 25 | -2.2 | |||||||
| 2 | 6.6 | 27 | 2.2 | 2 | -3.3 | 26 | -2.2 | |||||||
| 3 | 6.1 | 28 | 2.2 | 3 | -3.3 | 27 | -2.2 | |||||||
| 4 | 4.9 | 29 | 2.2 | 4 | -3.2 | 28 | -2.2 | |||||||
| 5 | 4.2 | 30 | 2.2 | 5 | -3.2 | 29 | -2.2 | |||||||
| 6 | 3.4 | 31 | 2.2 | 6 | -2.9 | 30 | -2.2 | |||||||
| 7 | 3.2 | 32 | 2.2 | 7 | -2.7 | 31 | -2.2 | |||||||
| 8 | 3.0 | 33 | 2.2 | 8 | -2.7 | 32 | -2.2 | |||||||
| 9 | 2.9 | 34 | 2.2 | 9 | -2.7 | 33 | -2.1 | |||||||
| 10 | 2.9 | 35 | 2.1 | 10 | -2.6 | 34 | -2.1 | |||||||
| 11 | 2.7 | 36 | 2.1 | 11 | -2.6 | 35 | -2.1 | |||||||
| 12 | 2.7 | 37 | 2.1 | 12 | -2.6 | 36 | -2.1 | |||||||
| 13 | 2.7 | 38 | 2.1 | 13 | -2.5 | 37 | -2.1 | |||||||
| 14 | 2.6 | 39 | 2.0 | 14 | -2.5 | 38 | -2.1 | |||||||
| 15 | 2.6 | 40 | 2.0 | 15 | -2.5 | 39 | -2.1 | |||||||
| 16 | 2.5 | 41 | 2.0 | 16 | -2.5 | 40 | -2.1 | |||||||
| 17 | 2.5 | 42 | 2.0 | 17 | -2.5 | 41 | -2.1 | |||||||
| 18 | 2.3 | 43 | 2.0 | 18 | -2.4 | 42 | -2.0 | |||||||
| 19 | 2.3 | 44 | 2.0 | 19 | -2.4 | 43 | -2.0 | |||||||
| 20 | 2.3 | 45 | 2.0 | 20 | -2.4 | 44 | -2.0 | |||||||
| 21 | 2.3 | 46 | 2.0 | 21 | -2.3 | 45 | -2.0 | |||||||
| 22 | 2.3 | 47 | 2.0 | 22 | -2.3 | 46 | -2.0 | |||||||
| 23 | 2.3 | 48 | 2.0 | 23 | -2.3 | 47 | -2.0 | |||||||
| 24 | 2.3 | 49 | 2.0 | 24 | -2.2 | 48 | -2.0 | |||||||
| 25 | 2.2 | 50 | 2.0 | |||||||||||
KEGG pathway analysis of differentially expressed genes identified by microarray analysis
| No. | KEGG classification | Pathway | Number of significant genes | Increased genes | Decreased genes | |
|---|---|---|---|---|---|---|
| 1 | Immune system | Th1 and Th2 cell differentiation | 7 | < 0.001 | ||
| 2 | Th17 cell differentiation | 6 | < 0.001 | |||
| 3 | T cell receptor signaling pathway | 6 | < 0.001 | |||
| 4 | Antigen processing and presentation | 5 | < 0.001 | |||
| 5 | Hematopoietic cell lineage | 5 | < 0.001 | |||
| 6 | Complement and coagulation cascades | 5 | < 0.001 | |||
| 7 | Natural killer cell mediated cytotoxicity | 4 | < 0.001 | |||
| 8 | NOD-like receptor signaling pathway | 4 | < 0.01 | |||
| 9 | RIG-I-like receptor signaling pathway | 3 | < 0.01 | |||
| 10 | Immune diseases | Primary immunodeficiency | 5 | < 0.001 | ||
| 11 | Systemic lupus erythematosus | 5 | < 0.001 | |||
| 12 | Graft-versus-host disease | 3 | < 0.01 | |||
| 13 | Signal transduction | PI3K-Akt signaling pathway | 10 | < 0.001 | ||
| 14 | Jak-STAT signaling pathway | 4 | < 0.01 | |||
| 15 | MAPK signaling pathway | 4 | < 0.01 | |||
| 16 | NF-kappa B signaling pathway | 3 | < 0.05 | |||
| 17 | Signaling molecules and interaction | Cell adhesion molecules (CAMs) | 5 | < 0.001 | ||
| 18 | ECM-receptor interaction | 4 | < 0.001 | |||
| 19 | Cytokine-cytokine receptor interaction | 4 | < 0.01 | |||
| 20 | Cellular community | Focal adhesion | 6 | < 0.001 | ||
| 21 | Cell growth and death | Apoptosis | 4 | < 0.01 | ||
| 22 | Transport and catabolism | Phagosome | 9 | < 0.01 | ||
| 23 | Lipid metabolism | alpha-Linolenic acid metabolism | 2 | < 0.05 | ||
| 24 | Translation | Ribosome | 7 | < 0.01 | ||
| 25 | Nervous system | Neurotrophin signaling pathway | 3 | < 0.05 | ||
| 26 | Sensory system | Olfactory transduction | 12 | < 0.001 |
Densitometry analysis of upregulated proteins (n = 24)
| No. | Protein name | Relative fold change |
|---|---|---|
| 1 | IL-2 | 27.4 |
| 2 | IL-27 | 19.3 |
| 3 | IL-17 | 13.1 |
| 4 | MIP-1beta | 10.2 |
| 5 | IL-23 | 7.2 |
| 6 | IL-1beta | 6.4 |
| 7 | IL-1ra | 4.6 |
| 8 | MIP-2 | 4.2 |
| 9 | MCP-5 | 4.1 |
| 10 | TIMP-1 | 4.0 |
| 11 | TARC | 3.9 |
| 12 | IL-3 | 3.9 |
| 13 | TREM-1 | 3.8 |
| 14 | TNF-alpha | 3.4 |
| 15 | IP-10 | 2.9 |
| 16 | MIG | 2.9 |
| 17 | BLC | 2.7 |
| 18 | I-TAC | 2.5 |
| 19 | RANTES | 2.5 |
| 20 | IL-4 | 2.4 |
| 21 | IL-6 | 2.4 |
| 22 | IL-16 | 2.2 |
| 23 | IL-5 | 2.2 |
| 24 | IL-10 | 2.0 |
Proteins differentially expressed in the blood of control and CIA mice. (A) Classification of upregulated proteins
| No. | Classification | Identified proteins | Number of proteins |
|---|---|---|---|
| 1 | Cytokine-cytokine receptor interaction | IL-2, IL-27, IL-17, MIP-1beta, IL-23, IL-1beta, IL-1ra, MIP-2, MCP-5, TARC, IL-3, TNF-alpha, IP-10, MIG, BLC, I-TAC, RANTES, IL-4, IL-6, IL-5, IL-10 | 21 |
| 2 | Jak-STAT signaling pathway | IL-2, IL-27, IL-23, IL-3, IL-4, IL-6, IL-5, IL-10 | 8 |
| 3 | Th17 cell differentiation | IL-2, IL-27, IL-17, IL-23, IL-1beta, IL-1ra, IL-4, IL-6 | 8 |
| 4 | Rheumatoid arthritis | IL-17, IL-23, IL-1beta, MCP-5, TNF-alpha, RANTES, IL-6, IL-16 | 7 |
| 5 | Hematopoietic cell lineage | IL-1beta, IL-1ra, IL-3, TNF-alpha, IL-4, IL-6, IL-5 | 7 |
| 6 | NOD-like receptor signaling pathway | IL-1beta, MIP-2, MCP-5, TNF-alpha, RANTES, IL-6 | 6 |
| 7 | Graft-versus-host disease | IL-2, IL-1beta, TNF-alpha, IL-6, IL-10 | 5 |
| 8 | NF-kappa B signaling pathway | MIP-1beta, IL-1beta, IL-1ra, TNF-alpha, BLC | 5 |
| 9 | T cell receptor signaling pathway | IL-2, TNF-alpha, IL-4, IL-5, IL-10 | 5 |
| 10 | PI3K-Akt signaling pathway | IL-2, IL-3, IL-4, IL-6 | 4 |
| 11 | Th1 and Th2 cell differentiation | IL-2, IL-4, IL-5 | 3 |
| 12 | MAPK signaling pathway | IL-1beta, IL-1ra, TNF-alpha | 3 |
| 13 | Systemic lupus erythematosus | TNF-alpha, IL-10 | 2 |
| 14 | HIF-1 signaling pathway | TIMP-1, IL-6 | 2 |
| 15 | RIG-I-like receptor signaling pathway | TNF-alpha, IP-10 | 2 |
| 16 | Apoptosis | IL-3, TNF-alpha | 2 |
| 17 | Natural killer cell mediated cytotoxicity | TNF-alpha | 1 |
| 18 | Antigen processing and presentation | TNF-alpha | 1 |
Figure 2Validation of microarray and proteome array results by qRT-PCR. The expression of each gene shown in the figure was confirmed by qRT-PCR using specific primers. β-Actin served as an internal control. Data represent the mean ± SEM. *P < 0.05, **P < 0.01
Figure 3Validation of microarray and proteome array results by western blotting. (A) Western blotting was performed using blood samples from control and CIA mice. GAPDH served as an internal control. (B) Relative fold change in band intensity of target proteins normalized to GAPDH level. Data represent the mean ± SEM. *P < 0.05